AryoGen Bevacizumab Biosimilar Compares To Avastin
Iranian Player Has Ambitions In Biotech Space
Executive Summary
Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.